The Health Insurance Review and Assessment Service (HIRA) said it would operate a system to manage “super-expensive” drugs, such as Kymriah and Zolgensma, including their course of medication.The state-run agency said Wednesday that it would run the system to “manage expensive drugs” to enhance the
GC Wellbeing has signed a technology transfer and joint development agreement for GCWB204, its cancer cachexia treatment candidate, with MThera Pharma.In a European phase 2a clinical trial last year, GC Wellbeing confirmed the potential of GCWB204 as a treatment for cancer cachexia in multiple evalu
Lilly Korea's CDK4/6 inhibitor Verzenio (ingredient: abemaciclib) will be an alternative treatment for the complete recovery of early breast cancer patients with a high risk of recurrence, the company said Wednesday.In November, Lilly Korea obtained expanded indication approval from the Ministry of
SK Biopharmaceuticals presented the company’s roadmap and vision for its digital healthcare business ahead of CES 2023 at a media briefing in Seoul on Wednesday.For instance, SK Biopharma’s “Project Zero” aims to become a total healthcare solution provider by developing wearable devices converged wi
Helixmith said Wednesday that it has developed a new freeze-drying formulation for its gene therapy, Engensis (VM202), further improving advantages in its manufacturing process and obtaining a patent in the U.S.The new formulation forms a superior cake quality and increases the stability of Engensis
As China abandons its “zero-Covid” policy, the Korean pharmaceutical companies are guessing whether it would work as a crisis or an opportunity.The Chinese government issued quarantine guidelines that allowed people infected with Covid-19 to self-isolate and significantly eased the polymerase chain
Celltrion said Tuesday it has proved once again the safety and effectiveness of Truxima(ingredient: rituximab), a hematologic malignancy treatment, through the internal post-marketing surveillance(PMS) at the American Society of Hematology (ASH) 2022.The clinical trial is the data on 677 safety eval
A heated debate is going on whether to view the three CDK4/6 inhibitors – Ibrance, Kisqali, and Verzenio -- in treating breast cancer as the same drug group or as individual drug groups.These CKD (cyclin-dependent kinase)4/6 inhibitors are said to have changed the treatment paradigm of HR+ (hormone
SillaJen will increase corporate value by increasing the company’s capabilities to research and develop new drugs, its top manager said.SillaJen CEO Kim Jae-kyung remarked at a news conference Tuesday to present the company’s current R&D status and plans after resuming its stock trading in the tech-
LG Chem said Tuesday that it confirmed the safety and efficacy of Zemidapa as a dual add-on therapy for type 2 diabetes patients who do not respond well to metformin standard diabetes treatments in phase 3 clinical trial.Zemidapa combines Zemiglo (ingredient: gemigliptin), a type 2 diabetes treatmen
The court has postponed the initial ruling over the civil lawsuit between Medytox and Daewoong Pharmaceutical over the origin of the latter's botulinum toxin strains to next year.The suit is regarding Medytox filing a civil lawsuit against Daewoong, claiming that the latter stole the BTX strain thro
GC Biopharma said on Monday that its I.V.-Globulin SN inj. 10% (ingredient: human immunoglobulin-G) for treating autoimmune encephalitis patients demonstrated safety and efficacy in prospective clinical trials.Autoimmune encephalitis is a disease that causes neurological deficits through autoimmune
Orum Therapeutics said on Monday that its acute myeloid (AML) drug candidate, ORM-6151, demonstrated superior safety and efficacy compared to competing drugs in preclinical trials, at the American Society of Hematology (ASH) in New Orleans, the U.S.ORM-6151 is the second candidate material to utiliz
In early 2018, AstraZeneca proved Tagrisso (osimertinib)’s efficacy in improving the progression-free survival (PFS) of EGFE-mutation non-small cell lung cancer as its primary treatment based on a global phase 3 clinical trial of FLAURA study.Tagrisso also demonstrated its benefits in overall surviv
Samsung Biologics said on Sunday that it has been included in the Dow Jones Sustainability Index (DSJI), a global ESG representative evaluation index, for the second consecutive year. Also, it ranked second in the life service science industry.The DJSI selects the top 10 percent of globally listed c
Novartis said iptacopan, a targeted factor B inhibitor, proved effective in complement-inhibitor-naïve (including anti-C5 therapies) adults with paroxysmal nocturnal hemoglobinuria (PNH) in a phase 3 study.The Switzerland-based company announced on Thursday that iptacopan met the primary endpoint of
SK Biopharmaceuticals said that Angelini Pharma, its EU partner, has won sales approval for cenobamate, an epilepsy drug, in France.The company initially launched cenobamate, under the product name Ontozry, in the EU market after obtaining sales approval from the European Commission in March last ye
HanAll Biopharma said it would receive a $10 million milestone payment from Roivant Sciences, a Switzerland-based company, for the technology transfer regarding an investigational autoimmune disease treatment HL161 (ingredient: batoclimab).In a regulatory filing on Thursday, HanAll Biopharma said it
Huons will produce isoproterenol-based medicines, the supply of which has been suspended by Pfizer Korea.Huons has been selected to receive support from the Ministry of Food and Drug Safety in return for supplying essential national medicines stably and taking over the production of isoproterenol in
Jeil Pharmaceutical said on Thursday that the company will provide an exclusive domestic supply of osteoporosis treatment Bonviva (ingredients: ibandronate sodium) and Bonviva Plus (ibandronate sodium, cholecalciferol), in Korea.Jeil signed the exclusive sales deal with Pharmanovia, a U.K. pharmaceu